Arrowhead Pharmaceuticals Files for Regulatory Clearance to Begin Phase 1 Study of ARO-HSD for Treatment of Alcohol and Nonalcohol Related Liver Disease

Arrowhead Pharmaceuticals Files for Regulatory Clearance to Begin Phase 1 Study of ARO-HSD for Treatment of Alcohol and Nonalcohol Related Liver Disease

4 years ago
Anonymous $9ruWwTnhZq

https://www.businesswire.com/news/home/20191216005194/en/

PASADENA, Calif.--(BUSINESS WIRE)--Dec 16, 2019--

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has filed an application for approval to begin a Phase 1 clinical trial of ARO-HSD, the company’s investigational RNA interference (RNAi) therapeutic being developed as a treatment for patients with alcohol related and nonalcohol related liver diseases, such as nonalcoholic steatohepatitis (NASH).

Last Seen
2 hours ago
Reputation
0
Spam
0.000
Last Seen
36 minutes ago
Reputation
0
Spam
0.000
Last Seen
4 minutes ago
Reputation
0
Spam
0.000
Last Seen
6 hours ago
Reputation
0
Spam
0.000
Last Seen
44 minutes ago
Reputation
0
Spam
0.000
Last Seen
about an hour ago
Reputation
0
Spam
0.000
Last Seen
about an hour ago
Reputation
0
Spam
0.000
Last Seen
a couple of minutes ago
Reputation
0
Spam
0.000
Last Seen
about an hour ago
Reputation
0
Spam
0.000